This course has expired. View available courses.

Oncology

The Evolving Role of Immunotherapy in Mesothelioma and Metastatic NSCLC

Immunotherapies have made important advancements in oncology by expanding treatment options and demonstrating clinical benefits across many different cancer types.

For metastatic non-small cell lung cancer (NSCLC), treatments are evolving and the options available are increasing with the release of key clinical trial results. PD-L1 is a widely validated biomarker assay, which serves as a therapeutic target in this cancer type.

For previously untreated unresectable Malignant Pleural Mesothelioma (MPM), nivolumab plus ipilimumab is the only immunotherapy treatment approved by Health Canada.

This program explores the benefits and limitations of immunotherapy treatment options as well as theimportant clinical trials that have helped to guide their use in the management of metastatic NSCLC and MPM.


This program has received an educational grant or in-kind support from BMS.

DURATION

1 hr

PROFESSION

Specialist

# OF CREDITS

3

ACCREDITATION

MOC - Section 3

EXPIRY DATE

2022-06-03

Immunotherapies have made important advancements in oncology by expanding treatment options and demonstrating clinical benefits across many different cancer types.

For metastatic non-small cell lung cancer (NSCLC), treatments are evolving and the options available are increasing with the release of key clinical trial results. PD-L1 is a widely validated biomarker assay, which serves as a therapeutic target in this cancer type.

For previously untreated unresectable Malignant Pleural Mesothelioma (MPM), nivolumab plus ipilimumab is the only immunotherapy treatment approved by Health Canada.

This program explores the benefits and limitations of immunotherapy treatment options as well as theimportant clinical trials that have helped to guide their use in the management of metastatic NSCLC and MPM.


This program has received an educational grant or in-kind support from BMS.

Faculty

Penelope Bradbury, MB, BCh, FRACP, MD (UK)

Parneet Cheema, MD, MBiotech, FRCPC

Barbara Melosky, MD, FRCP(C)

Solange Peters, MD, PhD

Learning objectives

After viewing this expert Webinar, participants will be better able to:

  • Discuss the changing role of immunotherapy in the management of metastatic non-small cell lung cancer (NSCLC)
  • Assess the role of immunotherapy in the malignant pleural mesothelioma (MPM) patient pathway
  • Determine the role of combining immunotherapies for individuals with NSCLC or MPM

Accreditation

Credits for Royal College Specialists:
This event is an Accredited Self-Assessment program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Queen's University Office of CPD. You may claim a maximum of 1 hour (credits are automatically calculated). Session ID: 00013653

Credits for Health Professionals:
This is an accredited learning activity which provided up to 1 hour of Continuing Education.


This program has been developed in collaboration with the CPD Network Association and OncologyEducation.

Cost of course:  
Free
# of credits: 3
Duration: 1 hr

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.